Kuehne+Nagel invests in global vaccine distribution network

LinkedIn +

Kuehne+Nagel has opened airside pharmaceutical and healthcare hubs in Brussels, Belgium, and Johannesburg, South Africa, adding to its GxP-certified network of temperature-controlled facilities for the distribution of vaccines and other products.

K+N said that the proximity of the hubs to the tarmac at the airside facilities minimised the risk of temperature changes, ensuring the integrity of the product.

The Brussels facility consists of 167,335 sq ft of warehousing space and is fully connected to its recently extended Geel Contract Logistics pharmaceutical warehousing facility, as well as the pan-European K+N PharmaChain Road Logistics Network managed from Luxembourg.

The expanded K+N PharmaChain airside facility at the international airport in Johannesburg responds to all temperature-sensitive cargo handling, consolidation, and storage requirements, whilst also offering a number of value-added logistics services before distribution in South Africa or into the rest of Africa.

Yngve Ruud, member of the management board of Kuehne+Nagel, responsible for air logistics, said: “The new hubs in Brussels and Johannesburg will ensure that our pharma and healthcare customers can fully rely on Kuehne+Nagel to handle the specific challenges of integrity as well as provide end-to-end visibility and regulatory compliance along the logistics journey of their sensitive products.”

The company has more than 230 GxP-certified operations worldwide – included in the pharmaceutical and healthcare network are additional hubs offering solutions for temperature-controlled needs; they are located in the US, the UK, Denmark, Spain, Luxembourg, Italy, France, Singapore, India, Panama, the UAE, and Australia.

Share this story: